Therapeutic Drug Monitoring of Everolimus: Comparability of Concentrations Determined by 2 Immunoassays and a Liquid Chromatography Tandem Mass Spectrometry Method.

Ther Drug Monit

*Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Stuttgart, Germany; †Laboratori Clínic Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; ‡Division of Endocrinology, Diabetology, Vascular Medicine, Nephrology and Clinical Chemistry and Pathobiochemistry, Department of Internal Medicine IV, University of Tuebingen, Tuebingen, Germany; §Institute of Diabetes Research and Metabolic Diseases (IDM), Helmholtz Center Munich, University of Tuebingen, Tuebingen, Germany; and ¶German Center for Diabetes Research (DZD), Muenchen, Neuherberg, Germany.

Published: April 2017

Background: Therapeutic drug monitoring is recommended to guide therapy with the immunosuppressant everolimus (EVL) in solid organ transplantation to prevent rejections and to limit toxicity. For therapeutic drug monitoring, predose EVL concentrations are measured in whole blood mainly by liquid chromatography tandem mass spectrometry (LC-MS/MS). In addition, 2 immunoassays [Quantitative Microsphere System (QMS) EVL and Elecsys EVL] are commercially available. The aim of this study was to evaluate the comparability of EVL results determined with the 2 immunoassays and a validated LC-MS/MS test using samples from kidney, liver, and heart transplant (KT, LT, and HT, respectively) recipients.

Methods: Analysis of predose samples from KT (n = 56), LT (n = 60), and HT (n = 59) recipients, obtained at variable time points after transplantation, was performed by LC-MS/MS and with the 2 immunoassays. The QMS EVL assay was applied on Dimension Xpand Plus and the Elecsys EVL assay on cobas e 411 analyzer. Results were compared by the Spearman's rank correlation coefficient, unbiased Passing and Bablok linear regression test, and Bland-Altman plot.

Results: Results generated with both immunoassays correlated well with those of LC-MS/MS. An overestimation of EVL concentrations by the Elecsys EVL compared with LC-MS/MS was observed (mean bias: 34.2%). Using the QMS EVL, a small but significant negative deviation (mean bias: -8.0%) was found. Looking at KT, HT, and LT samples separately, the bias to LC-MS/MS seen with the Elecsys EVL was similar. With the QMS EVL, the best agreement was observed with the KT samples followed by LT and HT.

Conclusions: Results generated by the 3 methods are not consistent regarding their diagnostic value. Both laboratories and manufacturers should take care to inform their costumers about the between-method differences to avoid misinterpretation of the results in clinical practice.

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000376DOI Listing

Publication Analysis

Top Keywords

qms evl
16
therapeutic drug
12
drug monitoring
12
elecsys evl
12
evl
11
determined immunoassays
8
liquid chromatography
8
chromatography tandem
8
tandem mass
8
mass spectrometry
8

Similar Publications

Background: A new homogeneous affinity chrome-mediated immunoassay (ACMIA) "EVRO" from Siemens Healthcare was evaluated for therapeutic drug monitoring of everolimus (EVL) with automated sample pretreatment and compared with quantitative microsphere system (QMS) "EVER" from Thermo Fisher Scientific.

Methods: Imprecision, inaccuracy, and limit of quantitation (LoQ) of ACMIA/EVRO were verified using both hemolysate quality control (QC) samples and pooled whole blood specimens. The interchangeability of methods and the agreement of results were analyzed using 72 specimens (from 38, 30, and 4 kidney, liver, and lung transplant recipients, respectively).

View Article and Find Full Text PDF

Therapeutic Drug Monitoring of Everolimus: Comparability of Concentrations Determined by 2 Immunoassays and a Liquid Chromatography Tandem Mass Spectrometry Method.

Ther Drug Monit

April 2017

*Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Stuttgart, Germany; †Laboratori Clínic Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; ‡Division of Endocrinology, Diabetology, Vascular Medicine, Nephrology and Clinical Chemistry and Pathobiochemistry, Department of Internal Medicine IV, University of Tuebingen, Tuebingen, Germany; §Institute of Diabetes Research and Metabolic Diseases (IDM), Helmholtz Center Munich, University of Tuebingen, Tuebingen, Germany; and ¶German Center for Diabetes Research (DZD), Muenchen, Neuherberg, Germany.

Background: Therapeutic drug monitoring is recommended to guide therapy with the immunosuppressant everolimus (EVL) in solid organ transplantation to prevent rejections and to limit toxicity. For therapeutic drug monitoring, predose EVL concentrations are measured in whole blood mainly by liquid chromatography tandem mass spectrometry (LC-MS/MS). In addition, 2 immunoassays [Quantitative Microsphere System (QMS) EVL and Elecsys EVL] are commercially available.

View Article and Find Full Text PDF

Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies.

Sci Rep

October 2014

1] School of Pharmacy, China Medical University, Taichung, Taiwan 404, R.O.C. [2] Department of Medical Research, China Medical University Hospital, Taichung, Taiwan 404, R.O.C.

Curcumin, a specific secondary metabolite of Curcuma species, has potentials for a variety of beneficial health effects. It is nowadays used as a dietary supplement. Everolimus (EVL) is an immunosuppressant indicated for allograft rejection and cancer therapy, but with narrow therapeutic window.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!